US Supreme Court stays Fifth Circuit limits on mail-order mifepristone
→Mifepristone mail-order dispensing remains available while the stay is in force
Change
The US Supreme Court stayed the Fifth Circuit order that had suspended the FDA’s 2023 mifepristone REMS changes, preserving the remote-dispensing and mail-order framework while the case continues.
Why it matters
The order removes the immediate operational constraint created by the Fifth Circuit’s suspension of the 2023 REMS changes. Certified pharmacies, telehealth prescribers and manufacturers can continue operating under the current FDA mifepristone REMS while the emergency stay remains in place. The order does not resolve the merits of Louisiana’s challenge to FDA’s 2023 remote-dispensing framework.
Implications
- → Abortion telehealth providers and certified dispensing pharmacies must treat the Fifth Circuit’s in-person-dispensing constraint as stayed — mifepristone prescribing and mail-order dispensing can continue under the 2023 REMS while the Supreme Court stay remains operative.
- → Mifepristone manufacturers’ legal and regulatory teams must continue defending the 2023 REMS framework in the ongoing litigation — the Supreme Court stay preserves current distribution rules but does not decide the merits.
- → Pharmacy compliance teams dispensing mifepristone must keep operations aligned with the current FDA REMS rather than the pre-2023 in-person dispensing requirement — the stay prevents the Fifth Circuit’s suspension from taking immediate effect.
Full decision brief
See the decision layer
Use 1 free preview to unlock implications, who’s affected, what to watch, and Clarify for this brief.
2 free previews left this month · Resets 1 Jun
Source
View on SCOTUS